drugset / Trial / NCT01129310
First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The investigators hypothesize IXO chemotherapy will have an improvement in response rate and acceptable toxicity for uncurable metastatic gastric cancer compared to historical controls.
Timeline
- Start
- 2010-07
- Primary completion
- 2018-05-18
- Completion
- 2018-05-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 950 mg/m2 | Oral |
| Subject | Irinotecan | Small molecule | 160 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | Intravenous |